Sedana Medical AB (publ) announced that the company has submitted an application for marketing approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care in Switzerland. The marketing approval application is based on the strong results in Sedana Medical's pivotal phase III study, Sedaconda (SED001). In December 2020, Sedana Medical submitted a marketing approval application for Sedaconda in 15 of the EU member states, including Norway. If all goes well, Sedana Medical expects an approval in the EU during the second half of 2021. After that, an application for a second group of EU countries can be submitted.